Clinical Trial Update: Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) [Phase 1]

View source ↗

Summary

A Phase 1 study by Merck evaluated the glucoregulatory effects of a GLP-1 receptor activator (MK-0000-222) in adults with Type 2 Diabetes Mellitus; the trial co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0000-222

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2013-07-08